US Pharma MarketingECO 2026: indirect comparison favours Wegovy pill over Foundayo - Pharmaceutical Technology
At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management. The analysis compared outcomes from the Phase III OASIS-4 trial and ATTAIN-1 in adults with overweight or obesity without diabetes. Key opinion leaders interviewed by GlobalData recognised oral semaglutide as a meaningful addition to the obesity armamentarium. Credit: Uwe Aranas via Shutterstock.com. On 15 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from a post-hoc indirect treatment comparison of Wegovy (oral semaglutide 25mg) versus Foundayo (orforglipron 36mg capsule; orforglipron 17.2mg tablet equivalent),…
At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.
Source: Pharmaceutical Technology